Finance

Senarai
Sebab 600812 meningkat 10.05%?
Terokai Dengan Lebih Terperinci
600812:SHA
North China Pharmaceutical Co Ltd
CN¥6.57
+10.05%
(+0.60) 1H
15 Okt, 3:00:01 PTG GMT+8  ·   CNY
Semua simbol
SimbolHargaPerubahan% Perubahan
Menjana cerapan popular untuk 600812...
Buka
CN¥5.78
Tinggi
CN¥6.57
Rendah
CN¥5.71
Purata volum
50.81J
Volum
334.29J
Dividen
0.53%
Dividen suku tahunan
CN¥0.01
Tarikh tanpa dividen
11 Jun 2026
Nisbah H/P
91.58
tgi 52 mgu
CN¥6.63
rdh 52 mgu
CN¥4.11
EPS
CN¥0.07
Syer tertunggak
1.63B
Bilangan pekerja
10K
Buka
CN¥5.78
Tinggi
CN¥6.57
Rendah
CN¥5.71
Purata volum
50.81J
Volum
334.29J
Dividen
0.53%
Dividen suku tahunan
CN¥0.01
Tarikh tanpa dividen
11 Jun 2026
Nisbah H/P
91.58
tgi 52 mgu
CN¥6.63
rdh 52 mgu
CN¥4.11
EPS
CN¥0.07
Syer tertunggak
1.63B
Bilangan pekerja
10K
Cerita berita
Daripada sumber web dan rakan kongsi berita
Profil
North China Pharmaceutical Group Corp., is a pharmaceutical manufacturer in China. NCPC was one of the key construction projects during China's First Five-Year Plan. After five years of construction since the foundation date in June 1953, the first successful pharmaceutical production, started in June 1958. Being one of the antibiotic producers both in technology and production scale at that time, NCPC created a history of commercial production of antibiotics in China. It has 45 years of development experience. NCPC has been taking the lead in the Chinese pharmaceutical industry in key economic indexes, ranked as one of the Top500 Enterprises and the best profit-makers in China. By the end of 2002, the total assets of the company were valued at US$2 billion, with 18,500 employees. In 2002, NCPC claimed a domestic sales revenue of US$700 million and export sales of US$100 million. Wikipedia
Perihal North China Pharmaceutical Co Ltd
CEO-
Pekerja9.97K
Diasaskan20 Dis 1992
Ibu pejabat-
Sektor-
Laman web-
Laporan sebelumnyaSemua nilai dalam CNY
Loading Previous Earnings...
Hasil
Pendapatan bersih
Semua nilai dalam CNY
Sep 2025
Dis 2025
Mac 2026
Jun 2026
Hasil
2.21B
1.76B
2.15B
2.07B
Kos barangan yang dijual
1.59B
1.07B
1.53B
1.54B
Kos hasil
1.59B
1.07B
1.53B
1.54B
Perbelanjaan penyelidikan dan pembangunan
85.19J
85.95J
95.62J
84.71J
Jumlah perbelanjaan penyelidikan dan pembangunan
-
-
-
-
Perbelanjaan jualan, am dan pentadbiran
419.54J
414.91J
354.22J
304.68J
Belanja kendalian
504.74J
539.54J
495.25J
396.76J
Jumlah belanja kendalian
2.09B
1.61B
2.03B
1.94B
Pendapatan kendalian
116.01J
149.57J
128.11J
125.58J
Pendapatan bukan kendalian lain
-299.86K
-2.96J
-10.58J
6.02J
EBT termasuk item luar biasa
73.18J
70.19J
66.28J
57.65J
EBT tidak termasuk item luar biasa
45.54J
84.31J
61.80J
58.08J
Belanja cukai pendapatan
23.93J
24.28J
16.90J
16.15J
Kadar cukai berkesan
32.70%
34.59%
25.50%
28.02%
Belanja kendalian lain
4.82J
29.30J
27.82J
15.57J
Pendapatan bersih
35.01J
24.55J
35.47J
28.37J
Margin untung bersih
1.58%
1.40%
1.65%
1.37%
Perolehan bagi setiap syer
-
-
-
-
Pendapatan faedah dan pelaburan
19.41J
27.71J
19.26J
22.40J
Belanja faedah
-85.85J
-85.06J
-74.99J
-76.52J
Belanja faedah bersih
-66.43J
-57.35J
-55.73J
-54.13J
Caj susut nilai dan pelunasan
-
-
-
-
EBITDA
313.14J
371.92J
350.45J
367.38J
Keuntungan atau kerugian daripada jualan aset
-9.85K
-827.34K
-
-217.80K
Kandungan AI boleh mengandungi kesilapan. Ketahui lebih lanjut
BantuanHantar maklum balasPrivasiSyaratPenafian
Apl Google